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Abstract
Background: The Oxford–Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public
Health England (PHE) are commencing their 54th season of collaboration at a time when SARS-CoV-2 infections are likely to
be cocirculating with the usual winter infections.
Objective: The aim of this study is to conduct surveillance of influenza and other monitored respiratory conditions and to report
on vaccine uptake and effectiveness using nationally representative surveillance data extracted from primary care computerized
medical records systems. We also aim to have general practices collect virology and serology specimens and to participate in
trials and other interventional research.
Methods: The RCGP RSC network comprises over 1700 general practices in England and Wales. We will extract pseudonymized
data twice weekly and are migrating to a system of daily extracts. First, we will collect pseudonymized, routine, coded clinical
data for the surveillance of monitored and unexpected conditions; data on vaccine exposure and adverse events of interest; and
data on approved research study outcomes. Second, we will provide dashboards to give general practices feedback about levels
of care and data quality, as compared to other network practices. We will focus on collecting data on influenza-like illness, upper
and lower respiratory tract infections, and suspected COVID-19. Third, approximately 300 practices will participate in the
2020-2021 virology and serology surveillance; this will include responsive surveillance and long-term follow-up of previous
SARS-CoV-2 infections. Fourth, member practices will be able to recruit volunteer patients to trials, including early interventions
to improve COVID-19 outcomes and point-of-care testing. Lastly, the legal basis for our surveillance with PHE is Regulation 3
of the Health Service (Control of Patient Information) Regulations 2002; other studies require appropriate ethical approval.
Results: The RCGP RSC network has tripled in size; there were previously 100 virology practices and 500 practices overall in
the network and we now have 322 and 1724, respectively. The Oxford–RCGP Clinical Informatics Digital Hub (ORCHID) secure
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networks enable the daily analysis of the extended network; currently, 1076 practices are uploaded. We are implementing a central
swab distribution system for patients self-swabbing at home in addition to in-practice sampling. We have converted all our primary
care coding to Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) coding. Throughout spring and summer
2020, the network has continued to collect specimens in preparation for the winter or for any second wave of COVID-19 cases.
We have collected 5404 swabs and detected 623 cases of COVID-19 through extended virological sampling, and 19,341 samples
have been collected for serology. This shows our preparedness for the winter season.
Conclusions: The COVID-19 pandemic has been associated with a groundswell of general practices joining our network. It
has also created a permissive environment in which we have developed the capacity and capability of the national primary care
surveillance systems and our unique public health institute, the RCGP and University of Oxford collaboration.
(JMIR Public Health Surveill 2021;7(2):e24341) doi: 10.2196/24341
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Introduction
Background
The Oxford–Royal College of General Practitioners (RCGP)
Research and Surveillance Centre (RSC) is a network of general
practices and is now in its 54th season of surveillance and
vaccine effectiveness in its long-standing collaboration with
Public Health England (PHE) and predecessor bodies [1]. This
season is complicated by the likely cocirculation of
SARS-CoV-2 and its associated disease burden [2].
The RCGP RSC has been recruited as a nationally representative
population [3] that provides pseudonymized data for surveillance
of infectious diseases. However, the recent influx of practices
may mean we have to adjust for practice distribution and ensure
we recruit virology sampling practices that are evenly
distributed. The disease surveillance program is commissioned
by PHE and monitors 38 infectious diseases, including influenza;
at the start of 2020, monitoring extended to include COVID-19
[4].
The recently expanded RCGP RSC extracts pseudonymized
data from over 1700 general practices each week covering a
nationally representative [3] population of over 13 million. Data
from these practices are reported online in the RCGP’s Weekly
Return [5], which includes monitoring weekly rates of
influenza-like illness (ILI) and other communicable and
respiratory diseases for England. We also produce an annual
report [6]. The RCGP RSC data set includes all coded data and
all prescribed items, including vaccine exposure [3]. To manage
our extended network of practices, we have set up a new
analytics hub: the Oxford–Royal College of General
Practitioners Clinical Informatics Digital Hub (ORCHID) [7].
The RCGP RSC conducts virology surveillance each influenza
season. Given the onset of COVID-19, virological sampling
has expanded to approximately 300 general practices (see Figure
1). We have reported on which groups of patients were more
likely to test positive for COVID-19 [8], on excess mortality
[9], and the shift away from face-to-face consultations during
the first wave of COVID-19 pandemic [10].
The RCGP RSC is also active in serosurveillance. During the
2018-2019 influenza season, we successfully conducted our
first collection of serological samples from adults, linking them
to their respective medical records [11,12]. Sentinel networks
can provide a mechanism for systematic data collection and
linkage to medical records and health outcomes [13], as well
as sampling across the complete age range [14]. Current activity
has included supporting PHE household studies and collecting
convalescent sera from people previously infected with
COVID-19.
Finally, the RCGP RSC network has supported trials and studies
designated as high-priority public health research. These
included recruiting to the PRINCIPLE (Platform Randomised
trial of INterventions against COVID-19 In older peoPLE) trial
[15] and supporting recruitment to RAPTOR-C19 (RAPid
community Testing fOR COVID-19) [16].
This protocol sets out how the RCGP RSC will continue to
provide enhanced passive surveillance, virological and
serological surveillance from a subset of practices, and support
high-priority public health research.
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Figure 1. Royal College of General Practitioners Research and Surveillance Centre’s virology sampling sites in England. Distribution by type of
computerized medical record system is shown. EMIS: Egton Medical Information Systems; INPS: In Practice Systems; TPP: The Phoenix Partnership.
Aim
The aim of this protocol is to provide comprehensive
surveillance of influenza, COVID-19, and other monitored
conditions including health outcomes. The RCGP RSC network
will also collect samples for virological and serological analysis,
measure vaccine exposure and effectiveness, and support other
high-priority public health research.
Objectives
Our six objectives are as follows:
1. To conduct surveillance of influenza and other monitored
respiratory conditions, including COVID-19. This will be
primarily from primary care data but will also include
linkage to secondary care and mortality data sets to enable
reporting of health outcomes. We will provide observatories,
dashboards, and training to optimize data quality.
2. To collect virological and serological samples to report the
presence and spread of monitored conditions from a
nationally representative sample of practices.
3. To report vaccine uptake, estimate effectiveness, and
investigate adverse events of interest (AEIs). We will focus
on influenza vaccinations and possible new COVID-19
vaccines.
4. To support research to answer important public health
questions, including trials of early interventions in the
community, near-patient testing, and household spread.
5. Apply the Findable, Accessible, Interoperable, and Reusable
(FAIR) principles so that our data are findable, accessible,
interoperable, and reusable by other organizations.
6. To implement appropriate information and research
governance.
Methods
Overview
The methods include six components: (1) surveillance of
influenza, COVID-19, other monitored conditions, and
associated health outcomes; (2) virological surveillance and
serosurveillance; (3) monitoring vaccine uptake and
effectiveness; (4) supporting priority public health research; (5)
data curation; and (6) governance.
Surveillance of Influenza, COVID-19, Other Monitored
Conditions, and Associated Health Outcomes
We will collect pseudonymized, routinely collected, coded
clinical data, which has been coded into patient records, using
UK Systematized Nomenclature of Medicine Clinical Terms
(SNOMED CT) codes (SNOMED International), for enhanced
passive surveillance. This will entail a wide range of clinical
event data, including collection of monitored conditions, vaccine
exposure, AEIs, hospital admissions, intensive care, and deaths,
to monitor approved study outcomes and for any unexpected
public health emergencies. Effective interoperability and
communication will be facilitated by monthly pseudonymized
linkage, facilitated by NHS (National Health Service) Digital
and PHE [7], to secondary care and other data sources, including
Secondary Uses Service, the continuously updated source of
hospital data (see Textbox 1).
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Textbox 1. Linkage to other data sets to support surveillance and research; individual data sets may have limitations on their use to specific projects
and users.
NHS (National Health Service) Digital:
• Cancer Registration Data (reduced)
• Secondary Uses Service (SUS) Payment by Results Episodes
• SUS Payment by Results Outpatients
• SUS Payment by Results Accident and Emergency
• SUS Payment by Results Spells
• Mental Health Services Data Set
• Diagnostic Imaging Dataset
• Emergency Care Data Set (ECDS)
• COVID-19 Hospitalisation in England Surveillance System (CHESS) Dataset-CV19 NHS 111 Online
• Second Generation Surveillance System (SGSS): laboratory test reports
• Hospital Episode Statistics (HES; same granularity of supply as for SUS)
• Office of National Statistics (ONS) Mortality
• NHS 111 (free-to-call single nonemergency number medical helpline)
National Cancer Registration and Analysis Service (NCRAS):
• Cancer Registry (full)
• Chemotherapy data set
• Radiotherapy data set
We have converted all our primary care coding to SNOMED
CT coding and are using this throughout our data processing
[17] (see Multimedia Appendix 1). We have been at the forefront
of ensuring that primary care systems code cases correctly and
that we comprehensively capture historic data [18]. This has
included the development of database-linked tools to
programmatically search SNOMED CT for relevant tools. The
hierarchical nature of SNOMED CT is that it requires machine
searching rather than manual searching (see Multimedia
Appendix 2). This will continue to deliver effective COVID-19
surveillance in parallel with the annual influenza surveillance
this season.
We will enhance surveillance through the provision of
dashboards and observatories to provide feedback about levels
of care compared to other practices in our network and to
improve data quality, clinical care, and patient safety. There
will be a particular focus on data quality, including the recording
of ILIs, the use of the RCGP RSC case definition (see Textbox
2 [19-21]), recording of upper and lower respiratory tract
infections, and recording of suspected COVID-19 cases, with
an emphasis on recording episode type (ie, whether this is a
new case or a follow-up). We will programmatically adjust for
when episode type is not recorded [18,22].
This year we will extend our virology sampling window to 10
days. We will also report on health outcomes, including
mortality [9] (see Figure 2).
Textbox 2. Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) case definitions of influenza-like illness (ILI).
The RCGP RSC definition of ILI:
• An acute respiratory illness with a temperature measured as, reported as, or plausibly ≥38 °C and cough, with onset within the past 10 days.  ILI
cases should not have another more plausible diagnosis. ILI cases have a sudden onset, and there are often symptoms suggestive of systemic
upset—myalgia, fatigue, malaise, headache, etc.  RCGP RSC stresses the notion of symptoms within 10 days of onset to differentiate acute
episodes, with swabs only wanted within 7 days of onset.
• This definition is compatible with the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC)
definitions [19,20]. The WHO definition has the highest specificity (21.4%) and the ECDC definition has the highest sensitivity (96.1%) [21].
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Figure 2. Royal College of General Practitioners Research and Surveillance Centre observatory showing mortality through the first wave of the
COVID-19 pandemic in England. Deaths per 100,000 population are displayed over the International Organization for Standardization (ISO) weeks for
2019 and 2020.
Virological Surveillance and Serosurveillance
A volunteer subset of practices will conduct virological
surveillance (see Multimedia Appendix 3). They will conduct
or arrange virological sampling of patients presenting with ILI
or lower respiratory tract infection, including acute bronchitis
and bronchiolitis in children under the age of 5 years. We will
include those suspected to have, or have been exposed to,
COVID-19 who have persistent cough, loss of taste and/or smell,
shortness of breath, history of fever, and/or the presence of a
wheeze. We will look for practices to collect 20 samples per
week; additional samples can be collected if the spread that is
present is within a household or a communal establishment.
Practices will receive feedback via dashboards [23] (see Textbox
3 [5,24-28]). Our target is to collect 600 samples per week across
all age bands.
The anticipated changes in the coming year are as follows:
1. We will reduce the burden of information collected on the
virology request form. Thus, a common but reduced set of
data will be collected for all patients offered virology
sampling. Vaccination history and a record of their
comorbidities will have already been collected electronically
as part of the standard data extract. However, we will stress
the importance of recording the NHS number as a unique
identifier, to help ensure efficient linkage of clinical data
to test results.
2. People who volunteer to self-swab will be given a voucher
code they can use online to arrange for a sample to be sent;
those in the surgery will have a swab taken by their general
practitioner or practice team, and this will be sent through
the post to the PHE reference laboratory. Patients taking
self-swabs should be given their NHS number to include
in their swab request to improve data matching.
3. All results will be sent to practices online via the e-Lab
system [29]; patients who self-swab and provide a mobile
number will additionally receive their results by text
message (see Figure 3).
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Textbox 3. Dashboards, online support, and observatories—also called weekly returns—to monitor and support data recording and key public health
projects.
Practice Dashboard
My Practice Dashboard [24]
All practices:
• Seasonal wellness: all practices can see vaccine uptake and incidence of key monitored conditions
• COVID-19: all practices will compare their incidence of COVID-19 with the rest of the network
Volunteer practices involved in specific surveillance or trials:
• Virology: for practices participating in specimen collection; in-practice and home tests
• Serology: for practices to observe their serology sampling; primarily by age band
• PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older peoPLE ) trial: to help practices know their level of
recruitment
• Online support:
• Facebook page [25]
• Twitter account [26]
• Podcast [27]
Observatories and Weekly Returns
Oxford–Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) weekly return:
• Twice weekly report—during the pandemic—on influenza, COVID-19, and other monitored conditions; reports are published at the RCGP RSC
website [5]—follow the “RSC Communicable and Respiratory Disease report” link on the “Public Health Data” page; this is the 54th year of
this report
Observatories [28]. We produce weekly reports online for the observatories, which provide an interactive weekly return of national data;
these are as follows:
• Seasonal wellness
• COVID-19
• Mortality
• Virology sampling
• Serology sampling
• PRINCIPLE trial eligible patients
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Figure 3. Flowchart for case identification and sampling for the 2020-2021 season surveillance. The National Health Service (NHS) number is a vital
unique identifier for all forms across virology and serology, including for patients requesting a test kit at home. ILI: influenza-like illness; LRTI: lower
respiratory tract infection; PHE: Public Health England; PRINCIPLE: Platform Randomised trial of INterventions against COVID-19 In older peoPLE;
SoB: shortness of breath.
A volunteer group of practices will also participate in serological
surveillance. The largest project will be the opportunistic
collection of an extra blood sample from patients undergoing
a routine blood test. Practices will be asked to collect across
age bands (aged 10 years and above) (see Figure 4), with
feedback provided to general practices via a dashboard and
overall via an observatory [30]. We are now recruiting practices
from areas with more ethnically mixed populations to provide
greater insight into disease spread in ethnic minority populations.
Other serology projects include extended serosurveillance in a
subset of patients with positive virology tests (n=63) as well as
recruiting and sampling patients included in the PHE-led
household contacts of confirmed COVID-19 cases (HOCO)
study [30]. We are piloting responsive surveillance in areas with
higher disease incidence.
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Figure 4. Number of serological surveillance samples collected per week. The program was initiated in week 11; we have been taking active steps to
encourage similar numbers across age bands per week.
Monitoring Vaccine Uptake, Effectiveness, and
Adverse Events of Interest
Capturing vaccine exposure is critical to conducting vaccine
effectiveness studies. With an increasing range of vaccines
available, capturing exposure data when not recorded within
the practice, beyond the fact that a vaccine has been given,
presents significant challenges [31]. Further issues include
difficulties capturing vaccine batch numbers [32]. We will ask
practices to preload the vaccine brands and batch numbers
online.
We plan to continue to report AEIs following vaccination using
routinely collected data, though we would have the capability
to provide patient AEI reporting cards if commissioned for
COVID-19 or other vaccines [33,34]. Practices will be provided
with prompts to improve coding. Good data quality regarding
AEI recording may identify any differences between influenza
vaccine types, to elucidate whether egg- or cell-based vaccines
with or without adjuvants are associated with different rates of
AEIs. There may also be up to six types of COVID-19 vaccines
available for which we may be able to provide uptake and AEI
data.
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Supporting Priority Public Health Research
Overview
The RCGP RSC will support a range of research (see
Multimedia Appendix 4), with the PRINCIPLE [15] and
RAPTOR-C19 [16] trials as the top priorities. The RCGP RSC
is a member of a number of European studies, including a
point-of-care testing study and data sharing as part of the DRIVE
(Development of Robust and Innovative Vaccine Effectiveness)
consortium [35,36] and a European study of respiratory syncytial
virus epidemiology [37]. In partnership with PHE, we are also
members of the I-MOVE (Influenza–Monitoring Vaccine
Effectiveness in Europe) consortium, which has extended its
work into COVID-19 [38].
We will support two ethically approved generic protocols for
COVID-19 research: DECISION-COVID (DEfining the
CharacterIStIcs Of Individuals with suspected Novel
COronaVIrus Disease and risk factors for development of the
disease) and MAINROUTE (Monitoring Attendance,
INvestigation, Referral, and OUTcomEs in primary care: impact
of and recovery from COVID-19 lockdown).
DECISION-COVID provides a framework for looking at
medications that might impact on COVID-19 outcomes;
MAINROUTE assesses the impact of lockdown on the wider
implications to care (see Multimedia Appendix 4). We have
already reported on how lockdown has led to a reorganization
of primary care service delivery [10]; in addition, we are part
of the RECAP (Remote COVID-19 Assessment in Primary
Care) early warning score validation study, which was set to
start in September 2020 [39].
Statistical Methods
A range of statistical methods will be used that are appropriate
to the area of surveillance or the research undertaken. We will
use propensity matching and a wide range of other methods to
work within the constraints of routine data [40].
Vaccine effectiveness will be assessed using test-negative design
[41,42]. Patients meeting the predefined clinical criteria will
undergo laboratory testing for specific circulating viruses.
Patients who test positive will comprise the cases; patients who
test negative to both influenza and COVID-19 will form the
control group. In the clinical at-risk populations, as defined by
NHS England, vaccine effectiveness will be calculated as
follows: (1 − adjusted vaccination odds ratio) × 100% [42]. This
will be estimated overall and stratified by influenza virus
subtype for all ages. Cohort analysis will also be performed
with vaccine effectiveness estimated as 1 – risk in vaccinated
subjects and 1 – risk in unvaccinated subjects, with adjustment
for confounding variables.
We will report AEIs using self-controlled case series design
[43,44]. An exposure period will be identified shortly after
vaccination, and a baseline period will form the remainder of
the observation period. The frequency of AEIs will be compared
to identify any invariant confounding [44,45]. We will use
self-controlled case series to report the different rates of AEIs
between vaccines; biases should be similar between vaccines.
For influenza, we will continue to use the European Medicines
Agency–specified AEIs; should COVID-19 vaccination
commence this season, we will identify AEIs. Notwithstanding
the enlarged size of the network, we are not large enough to
detect rare events.
Data Curation
We strongly support the FAIR principles [46]. We are a
founding member of the Health Data Research UK Data
Alliance, and our data are included in their metadata, with our
activities ranked as high priority [47]. We are creating a data
set within ORCHID, an observational research platform that
has themed databases that can be made readily available to
researchers simultaneously; these will be used to support
DECISION-COVID and other studies (see Multimedia
Appendix 4) [48]. Additionally, we are linking over 50 years
of virology and RCGP RSC data, as part of the Wellcome
Trust–funded quinquagenarian database project, to make these
data more accessible [49]. ORCHID [7] aims to provide a large,
near-real-time–themed primary care health informatics hub for
the use of data from consenting patients in clinical trials and to
supplement existing disease surveillance using in situ network
data without large-scale data extraction. We aim to make outputs
available using common data models, which we will be
providing to the European Health Data Evidence Network
[50,51].
Governance
The surveillance for the coming year will be initiated by a joint
letter to volunteer practices informing them of their role in the
surveillance process. The legal basis for our surveillance with
PHE is defined as Health Protection under Regulation 3 of the
Health Service (Control of Patient Information) Regulations
2002 and is approved annually by the PHE Caldicott Guardian;
other studies require appropriate ethical approval. The
University of Oxford is compliant with the General Data
Protection Regulation and the NHS Digital Data Security and
Protection policy.
We want to minimize any risk associated with taking part in
this surveillance. Infection prevention and control advice will
follow extant national guidance. Our member practices already
have most processes in place to meet Regulation 12 of the Health
and Social Care Act 2008 (Regulated Activities) Regulations
2014, concerning safe care and treatment, and are periodically
inspected by the Care Quality Commission [52]. Our training
will include reminders about safe handling of specimens and
will recommend revision of infection control measures, where
needed.
Results
Surveillance Network Development
The COVID-19 pandemic has led to considerable numbers of
practices joining the Oxford–RCGP RSC network. The
collaboration with EMIS (Egton Medical Information Systems)
Health has made it much easier for practices to contribute
pseudonymized patient data at rapid speed and at a large scale.
The network has tripled in size since January 2020, from 500
practices to 1724. Of these practices, 1076 are using the new
ORCHID platform being developed in collaboration with EMIS
for direct data extract. Pseudonymized data from over 13 million
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patients has enabled the growth of a rich database from which
researchers are developing a deeper understanding of the
COVID-19 pandemic and other diseases in general practice.
We have opened a Facebook page and Twitter account to
provide more online information and help (see Textbox 3).
Virological Surveillance and Serosurveillance
We formerly had 100 practices taking part in the national
influenza surveillance scheme. This has expanded to 322 for
COVID-19 surveillance. As of August 17, 2020, the surveillance
system has collected 5357 swabs and detected 581 cases of
COVID-19 through extensive virological sampling. A total of
273 practices have contributed toward serosurveillance,
collecting a baseline of 2000 samples and an additional 1000
samples per week. A total of 19,761 samples have been collected
for serology as of August 17, 2020. We are also piloting
serosurveillance in two cities in the northwest of England with
a high incidence of COVID-19.
Monitoring Vaccine Uptake and Effectiveness
We started collecting vaccine brands and batch numbers via our
online portal on September 1, 2020, for the upcoming influenza
season. We have made provisions in our dashboards and
observatories for the changed vaccination policy for influenza
and for virology sampling in the coming season. We have
successfully piloted the secure transfer of data between
ORCHID and PHE using the OxFile – Large File Exchange
Service secure data transfer system [53].
Supporting Priority Public Health Research
We have recruited 517 practices into the PRINCIPLE trial. A
total of 440 patients have had successful screening and have
been randomized. As of August 13, 2020, 537 patients have
been recruited via general practitioner practices set up as official
recruiting sites. Oxford–RCGP RSC practices have recruited
81.9% of these patients.
Data Curation
Our key focus is the development of ORCHID and accessibility
of our extended data set. Currently, 1076 practices use the
ORCHID virtual server.
Governance
We will put in place processes to allow approved researchers
access to ORCHID.
Discussion
Principal Findings
We have tripled the sign-up to the Oxford–RCGP RSC and are
well on our way to operationalizing this new extended network
ahead of the coming winter, in a season complicated by
SARS-CoV-2 circulation and an extended flu vaccination
program.
The Oxford–RCGP RSC now has in place the most
comprehensive set of linked data in its history, supplemented
by reference lab virology and serology. Over half of our network
will have data available on a daily basis via unprecedented,
timely, remote researcher access to our themed data sets.
We have also introduced self-swabbing to increase safety and
convenience for patients and practices, to enable direct relay of
COVID-19 results to patients, and to reduce the burden of form
filling. We have also extended the number and sophistication
of our dashboards and observatories, adding interactivity and
more extensive help.
Safety of practices remains our primary concern and we are not
aware of any increased risk to practice staff or other patients
from involvement in surveillance. Personal protective equipment
was difficult to source at the start of the pandemic, as were
SARS-CoV-2 tests. Both are now much more available to
primary care.
Comparison With Previous Work
Pandemic preparedness is part of the role of the RCGP RSC.
The RCGP RSC has operated for over 50 years and has been
involved in collecting samples to monitor disease and vaccine
effectiveness through the Hong Kong flu pandemic of
1968-1969, the Russian flu of 1977-1978, the 2009 swine flu
pandemic [54,55], and the first wave of the COVID-19 pandemic
earlier this year.
The introduction of self-swabbing kits this year will enable
wider distribution, allowing for an increase in the number of
people to be tested. People in self-isolation and quarantine can
access testing kits without leaving the confines of their homes,
negating the risk of transmission to others with whom they
interact with in transit [6]. Self-swabbing appears to be reliable
[56,57].
We have shown considerable adaptability so far this year,
tackling a wide range of issues and producing publicly available
dashboards as well as research outputs [6-8,10,22].
Strengths and Limitations
The strengths of our network lie in the willingness of practices
to share data and the quality of those data. The Oxford–RCGP
RSC team has a deep understanding of primary care data, the
context of data recording, and the ability to process routine data.
We have developed even closer relationships with computerized
medical records system suppliers, especially EMIS. We have a
long-term partnership with PHE and its predecessor bodies.
There is a good understanding of the strengths and limitations
of routine data and the capabilities of primary care.
The limitations of our system are those of all routine data, in
that the data may not be complete or accurate. Ensuring we have
good data quality is key for the reliability of our screening.
There are few available comparators, but we know the network
detects more new cases of some cardiovascular diseases than
others [58]. Given our ambitious program of scaling, via a new
pathway for virology surveillance based on patient-completed
data, a further limitation is that these data are currently not
linked back into their general practice record. We have also
found that the success of open access testing means that
individuals can be tested more quickly at a public testing station
[59] than self-swabbing via a test through the surveillance
system, thereby restricting the extent of possible collection.
While our network is large enough to report the relative
incidence of common AEIs following influenza vaccination,
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comparing brands and vaccine types, it may be too small to
comment on very rare events. Little is known about the
anticipated AEIs with the new COVID-19 vaccine, so it is
currently unclear what role we could play.
While we are part of many European and international networks,
we did not have the opportunity to rapidly produce a shared
international protocol. However, this document will include the
learning from our decades of joint surveillance. It is being made
available as a preprint to enable comments to be made and to
allow learning to be shared.
Conclusions
The Oxford–RCGP RSC has had a groundswell of interest in
membership during the first wave of the COVID-19 pandemic.
We have grown in network size and functionality. Our
challenges are to maintain data quality and to help support our
practices in identifying sufficient volunteers to deliver the
required number of samples as we take on more general practice
members. Another challenge is the uncertainty of a winter
season with cocirculating COVID-19. The pace of change in
our understanding of COVID-19 requires us to move ahead
rapidly, rather than in close coordination with others. This
protocol sets out our approach to surveillance in the coming
season and makes our approach widely available for comment
or use by others involved in surveillance.
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